Researchers at Moffitt Cancer Center have found that tapping into the body's own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of ...

Lymphedema Treatment Act: A Critical Step for Cancer Survivors, but Unresolved Equity Gaps Persist Patients with advanced melanoma resistant to immune checkpoint or BRAF/MEK inhibitors have treatment ...

Please provide your email address to receive an email when new articles are posted on . The addition of pembrolizumab to TIL therapy improved response rates among individuals with metastatic ...

Scientists from the Moffitt Cancer Center say they now have a better understanding why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings ...

Richmond, Va.-based VCU Health’s Massey Comprehensive Cancer Center has become the first facility in Virginia to offer tumor-infiltrating lymphocyte therapy for advanced stage melanoma patients. TIL ...

In a new study, TILs significantly predicted both distant disease-free survival and overall survival in early ERBB2-positive breast cancer. TIL levels ≥20% were associated with better outcomes when ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. It’s not common for cancer surgeons to turn their focus ...

Tumor-infiltrating lymphocytes (TILs) are immune cells that naturally recognize and penetrate tumors to kill cancer cells, making them a promising approach for treating solid tumors. This potential ...

The promise of tumor-infiltrating lymphocytes (TIL) therapy is expanding beyond melanoma to a wide range of solid tumors, but the path to clinical success remains complex. Variability in tumor tissue ...

Cohort 4 Early Data Shows 32.4% ORR by Investigator Assessment at 5.3 Months of Median Study Follow up Cohort 2 Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up and ...

Recent research is helping to expand the potential biomarker landscape in non–small cell lung cancer (NSCLC) and may soon ...